Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSG XX high-risk soft tissue sarcoma adjuvant and neoadjuvant chemo-radiotherapy
2007-001152-39Phase 2Completed
- Sponsor
- Scandinavian Sarcoma Group
- Start
- Apr 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of doxorubicin and ifosfamide in soft tissue sarcoma (STS) (2 arms), sponsored by Scandinavian Sarcoma Group. Primary endpoints: Metastasis-free survival and Cumulative incidence of local recurrence. Started Apr 2007; status: completed.
02
Drugs
doxorubicinifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2007-001152-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001152-39.